At present, the sales price of its anti aging u03b2 - nucleotides (NMS) in the US has been released. As soon as the news came out, the companys share price soared, and there were 8 trading limits within 10 days.
Due to the rapid rise, jindawei also attracted the attention of Shenzhen Stock Exchange and received an inquiry letter from the exchange on July 20. Its reply to the concern letter said: the product prospect is unknown, and it will not affect the actual performance of the company at present. Please pay attention to the investment risk.
On July 21, the opening price of jindawei slowed down, but it began to trade at about 10 oclock. Although the trading limit was opened subsequently, it was finally closed; on July 22, the trading limit board was closed again; on July 23, the intraday trading limit was increased again, and the final closing price was 6.4%.
In this view, although jindawei has repeatedly stated that its longevity drug NMN has no future, and it is not used to diagnose, treat, cure or prevent any disease, it still can not hold the capital markets pursuit of the concept and hold peoples persistence in Immortality. Once launched on the E-commerce platform, it sold out and detonated the whole capital market.
However, after a careful examination, we found that the raw material of the drug was only more than 30 yuan, and there were a series of doubts about its academic background and real utility
Is that really good?
Can NMN really resist aging?
However, on the side translation of the product, it says: the above statement is not certified by the U.S. Food and drug administration. This product is not intended to treat, cure or prevent any disease.
Its so paradoxical that its hard to understand.
It is reported that on July 19, Xiamen jindawei Group Co., Ltd. received a letter of concern, requiring the company to make supplementary disclosure on the specific production and sales of an anti-aging product u03b2 - nicotinamide mononucleotide (NMN), as well as the approval or certification of the product in the United States, and the scientific verification or practice of the actual utility of the product.
On July 20, jindawei issued an announcement on the reply to the concern letter of Shenzhen Stock Exchange, giving five references, and stating that DRB did not make a clear commitment to the actual utility of the product, and had clearly indicated that it would not be used for diagnosis, treatment, cure or prevention of any disease.
At the same time, 21 new health found that the clinical data directly supporting the efficacy of NMN were not enough.
In the promotion of Kingway products on tmall platform, it was mentioned that Professor David Sinclair supported oral NMN
21 new health further inquired the references mentioned in the publicity, and found an experiment with mice as the research object: after feeding NMN for one week for 22 months old mice, many indexes such as mitochondria could be reversed to the level at 6 months old, and the life span could be prolonged by 30%.
In conclusion, there is no evidence that David Sinclair supports NMN related products. Moreover, even if the animal experiment is effective, it can not be equated with prolonging life. Shi lichen told the industry media that animal tests cant show that the product has efficacy on human beings. If you want to prove the efficacy, first, we need to do independent pathological tests, second, animal experiments, and third, we need to carry out phase I, II and III clinical trials. Only animal experiments can not show that it is effective for human body.
Thirdly, David Sinclair also expressed his support for resveratrol in the product promotion.
21 new health looked up its third reference, a blog website named podcastnotes. It did find articles about David Sinclair and NMN, but did not find the evidence proving that David Sinclair was the author of the article. The credibility of the article is questionable.
At present, the effect of most anti-aging drugs is not ideal, and there are not many kinds of anti-aging drugs that can be directly used in clinical treatment. Fishman, a bioethicist at McGill University in Canada, once pointed out that there are two problems with anti-aging drugs
First, some anti-aging drugs that are accelerating the market may lead to patients only enjoying superficial treatment benefits, and their potential toxic and side effects will have to wait for a long time to be discovered, and it is difficult to pass the clinical audit;
Second, the research and development of anti-aging drugs requires a lot of funds, and the cycle is quite long. At present, most of the relevant R & D enterprises can only bypass to lock in diseases that may be caused by aging cells.
Do words such as Anti Age involve false propaganda?
It is worth noting that NMN can be anti-aging and anti-aging in product promotion, and some health care products even promote reducing cancer risk.
According to the first issue Bulletin of the Supreme Peoples court in 2019, the advertising content of health food must be true, and the health care function approved by the administrative department shall prevail. It shall not be changed and expanded, shall not contain false and exaggerated contents, and shall not involve the function of disease prevention and treatment. If the contents of a large number of publicity materials provided by the sales enterprises or distributors in promoting the health food are different from the efficacy stated in the product description of the health food, and indicate or imply that the health food has antibacterial, anti-inflammatory, anti-virus, anti-tumor, disease elimination and other pharmaceutical effects to varying degrees, it constitutes false publicity, and shall bear the responsibility for false publicity according to law.
Shi lichen, founder of Beijing Dingchen medical management consulting center, pointed out that NMN is a new resource, and new resources must be used in clinical trials in China to make health products. If the regulatory authorities do not approve (NMN) has the effect of prolonging life, you cannot publicize (prolong life) Mr. schlichen also said that in the United States, whether health products can be put on the market mainly depends on the safety, and the FDA will not control whether it is effective.
Can American health products be sold directly in China?
It is understood that the listing of health care products in China must be approved by China food and drug administration to obtain the only approval and batch number, commonly known as blue hat. According to Article 76 of Chinas food safety law, the health food imported for the first time shall be registered and filed with the food and drug administration. However, foreign dietary supplements entering the domestic market have not been included in the regulatory scope of health products.
In other words, dietary supplements in the United States are not regulated by FDA in the United States, nor are they regulated by health food related regulations after they are imported into China.
It is understood that jindawei was originally an enterprise engaged in feed production. Since 2015, the company has acquired a number of health care products production enterprises and transformed into enterprises engaged in the production and sales of health products.
What is the cost of the product?
In the product introduction, it was mentioned that its core components included resveratrol and u03b2 - nicotinamide mononucleotide (NMN). 21 new health inquired the purchase price of raw materials on Alibaba and Baidu AI respectively. The results showed that the wholesale price of resveratrol labeled as edible was about 1500 yuan / kg, while that of u03b2 - nicotinamide mononucleotide was about 1200 yuan / kg.
For example, according to the wholesale price of raw materials, the cost of resveratrol is 0.75 yuan, and that of u03b2 - nicotinamide mononucleotide is 0.384 yuan. Only considering the above two ingredients, the raw material cost of a bottle (30 products) of the health care product is only 34.02 yuan, which is far lower than the price of nearly 1600 yuan on its platform.
According to CITIC Securities, the prices of nicotinic acid and nicotinamide products at the front end of the NMN industrial chain are between 0.03-0.15 yuan / g, and the latest price is around 0.05 yuan / g. Compared with the price of front-end raw materials, the production cost of NMN in the future still has a large space to decrease, but the related progress mainly depends on the process development progress.
New health understands that jindawei is an old brand food additive manufacturer in China, which was established in November 1997. It is now the worlds largest supplier of coenzyme Q10 and an important VA supplier.
In recent years, Kingway has successively acquired doctors best, vitatech, prosupplies, zipfizz and other health care products companies, and participated in labrada and iherb companies, forming a whole industrial chain of health care products from upstream raw material supply to midstream production and processing to downstream channel sales, and its net profit has been continuously improved.
Which other enterprises are producing and selling related products?
According to CITIC Securities, the NMN market has just started, mainly dominated by three enterprises from Japan, the United States and Hong Kong, China. The main situation is as follows:
Source: Official Websites of all companies, CITIC Securities
It is understood that nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are not listed in the GRAS list, indicating that FDA believes that NR and NMN may pose risks to human body. In this regard, a medical doctor from the University of Sydney said that all the NR and NMN products listed in the United States are essentially playing the edge of the ball, and there is no authority certification.
In China, 21 new health inquired the national food and Drug Administration website and found that NR and NMN were not included in the national pharmacopoeia, and there was a lack of standardized and unified quality standards.
21 new health searched domestic NMN health products on tmall and Jingdong platforms, but no relevant results were found. It is understood that domestic enterprises involved in NMN research and development mainly include jindawei, YABEN chemical, Fengyuan pharmaceutical, etc.
Jiangsu Chengxin Pharmaceutical Co., Ltd., a subsidiary of 28.4% of Fengyuan Pharmaceutical Co., Ltd., has participated in the related technology research and development of NMN products, but there is no sales of this product at present.
On October 11, 2019, YABEN Chemical Co., Ltd. announced to participate in NMN product research and development, mentioning cultivating new profit growth points, developing and producing NMN and other biological enzyme preparations and related biotechnology products.
Some companies have the R & D and sales of industrial chain related products. For example, brother technology and HONGSUN subsidiary Anhui Ruibang have nicotinamide capacity. The API of Erkang pharmaceuticals wholly-owned subsidiary through GMP inspection includes nicotinic acid, etc. nicotinamide and nicotinic acid are NMN competitive products and can also be used as raw materials for NMN production, belonging to related companies of industrial chain.
CITIC Securities estimates that NMN health products market is expected to reach 100 billion in the long term. According to the current market penetration rate of health care products in different age groups and the consumption of NMN in different age groups (i.e. not taking NMN for 24 years old or below, taking 1 tablet a day for 25-44 years old, and taking 2 tablets a day for 45 years old and above), the corresponding market size is about 30.4 billion yuan for each 1% of the domestic health care product market. With the continuous promotion of anti-aging products in the future, if NMN can cover 3% of the current population taking health care products, its market size is expected to reach 100 billion. However, at present, the safety and effectiveness of its product ingredients are in doubt, and consumers and investors need to be cautious. In order to standardize the registration and filing of health food, according to the food safety law of the peoples Republic of China, the former State Food and Drug Administration issued the measures for the registration and filing of health food on July 1, 2016. On the morning of March 11, 2019, at the press conference of the second session of the 13th National Peoples Congress, when asked about the next step in the supervision of health care products, Zhang Mao, director of the State Administration of market supervision and administration, said that the current registration system of health care products should be reformed, and enterprises should make more self declaration and commitment, seek truth from facts, and should not be exaggerated. Source: Yang Bin, editor in charge of economic report in the 21st century_ NF4368
However, at present, the safety and effectiveness of its product ingredients are in doubt, and consumers and investors need to be cautious.
On the morning of March 11, 2019, at the press conference of the second session of the 13th National Peoples Congress, when asked about the next step in the supervision of health care products, Zhang Mao, director of the State Administration of market supervision and administration, said that the current registration system of health care products should be reformed, and enterprises should make more self declaration and commitment, seek truth from facts, and should not be exaggerated.